Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Dolutegravir + Rilpivirine (JULUCA) in Healthy Japanese Participants
NCT03984838Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Jun 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dolutegravir and rilpivirine in human immunodeficiency virus type 1 infection (HIV-1), sponsored by ViiV Healthcare. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero Extrapolated to Infinite Time, Area Under the Concentration-Time Curve From Time Zero to Last Time of Quantifiable Concentration and 13 more. Started Jun 2019; status: completed.
02
Drugs
dolutegravirrilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03984838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03984838.